WaveSense, Pisces Scientific Collaborate
News Sep 29, 2016
WaveSense, Inc has announced that it has signed a new strategic marketing relationship with Pisces Scientific Ltd. Pisces was founded and continues to be dedicated to the importation and distribution of innovative products and instruments for in vitro diagnostic and research labs focusing on cytogenetics, molecular genetics, and molecular pathology.
Pisces Scientific will now market and sell the WaveSense CE-IVD marked cell enrichment platform, a growing pipeline of cell enrichment products. Current CE-IVD products include the EpiSep®, direct to slide enrichment technology, as well as their proprietary paramagnetic bead technology for the selective isolation of cells expressing CD138.
William Curtis, WaveSense CEO, said that "Pisces Scientific has established itself as a trusted distribution partner due to their strong relationships with many of the country’s leading hospital and academic research laboratories." He added, "We look forward to working with Pisces Scientific and building on the synergy of this partnership. We will work together to meet the growing demands for selective cell enrichment for customers in the UK and Ireland."
Pisces Scientific Managing Director, Stewart Kennedy, added "As molecular diagnostics become an integral part of the diagnosis and treatment of cancer there is growing concern that the correct cell type is being evaluated. The WaveSense technology directly addresses this concern, and with this partnership, we will now be able to deliver the optimal solution to cytogenetic laboratories within the UK and Ireland."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.